Keyphrases
Chronic Lymphocytic Leukemia
100%
Fludarabine
100%
Relapsed or Refractory
100%
Rituximab
100%
Cyclophosphamide
72%
Pounding
45%
Evidence Review
36%
Survival Benefit
36%
Quality-adjusted Life Years
27%
Incremental Cost-effectiveness Ratio
18%
National Institutes of Health
18%
Clinical Excellence
18%
Single Technology Appraisal
18%
Randomized Controlled Trial
9%
Chemotherapy
9%
Cost-effectiveness
9%
Previous Treatment
9%
Clinical Efficacy
9%
Divergence
9%
Quality of Life Improvement
9%
Cyclophosphamide Treatment
9%
Progression-free Survival
9%
Appraisal Processes
9%
Overall Survival Benefit
9%
Chemotherapy-only
9%
Economic Model
9%
Relapsed or Refractory Acute Myeloid Leukemia
9%
Observation Time
9%
Clinical Costs
9%
Leukemia Patients
9%
Group Reports
9%
Cumulative Mortality
9%
Pharmacology, Toxicology and Pharmaceutical Science
Chronic Lymphatic Leukemia
100%
Fludarabine
100%
Rituximab
100%
Cyclophosphamide
81%
Chemotherapy
18%
Base
18%
Randomized Controlled Trial
9%
Overall Survival
9%
Progression Free Survival
9%